share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  05/09 16:14
Moomoo AI 已提取核心信息
On May 9, 2024, eFFECTOR Therapeutics, Inc. announced the entry into an At the Market Offering Agreement with H.C. Wainwright & Co., LLC, allowing the company to sell up to $50.0 million of its common stock. The sales will be made on the Nasdaq Capital Market and the company will pay a 3.0% commission to the Agent on the gross proceeds. There is no obligation for either party to proceed with the sale of any stock, and the number of shares sold, if any, as well as the prices and dates of sale, are not guaranteed. The agreement also includes indemnification provisions for the Agent. Concurrently, eFFECTOR Therapeutics terminated its previous agreement with Cantor Fitzgerald & Co., under which it had sold 1,075,405 shares for an aggregate offering price of $9.8 million. The termination was effective immediately, and no further sales will be made under the prior agreement. The new sales agreement and the termination of the old one were made pursuant to the company's effective registration statement and prospectus supplement filed with the SEC.
On May 9, 2024, eFFECTOR Therapeutics, Inc. announced the entry into an At the Market Offering Agreement with H.C. Wainwright & Co., LLC, allowing the company to sell up to $50.0 million of its common stock. The sales will be made on the Nasdaq Capital Market and the company will pay a 3.0% commission to the Agent on the gross proceeds. There is no obligation for either party to proceed with the sale of any stock, and the number of shares sold, if any, as well as the prices and dates of sale, are not guaranteed. The agreement also includes indemnification provisions for the Agent. Concurrently, eFFECTOR Therapeutics terminated its previous agreement with Cantor Fitzgerald & Co., under which it had sold 1,075,405 shares for an aggregate offering price of $9.8 million. The termination was effective immediately, and no further sales will be made under the prior agreement. The new sales agreement and the termination of the old one were made pursuant to the company's effective registration statement and prospectus supplement filed with the SEC.
2024年5月9日，Effector Therapeutics, Inc.宣布与H.C. Wainwright & Co., LLC签订市场发行协议，允许该公司出售高达5000万美元的普通股。销售将在纳斯达克资本市场上进行，公司将向代理人支付总收益的3.0％的佣金。任何一方都没有义务继续出售任何股票，也不能保证出售的股票数量（如果有）以及出售的价格和日期。该协议还包括对代理人的赔偿条款。同时，Effector Therapeutics终止了先前与Cantor Fitzgerald & Co. 的协议，根据该协议，该公司出售了1,075,405股股票，总发行价为980万美元。终止立即生效，根据先前的协议，将不再进行进一步的销售。新的销售协议和旧协议的终止是根据公司向美国证券交易委员会提交的有效注册声明和招股说明书补充文件签订的。
2024年5月9日，Effector Therapeutics, Inc.宣布与H.C. Wainwright & Co., LLC签订市场发行协议，允许该公司出售高达5000万美元的普通股。销售将在纳斯达克资本市场上进行，公司将向代理人支付总收益的3.0％的佣金。任何一方都没有义务继续出售任何股票，也不能保证出售的股票数量（如果有）以及出售的价格和日期。该协议还包括对代理人的赔偿条款。同时，Effector Therapeutics终止了先前与Cantor Fitzgerald & Co. 的协议，根据该协议，该公司出售了1,075,405股股票，总发行价为980万美元。终止立即生效，根据先前的协议，将不再进行进一步的销售。新的销售协议和旧协议的终止是根据公司向美国证券交易委员会提交的有效注册声明和招股说明书补充文件签订的。
有用
没用

该公告为独立文件：

独立文件1

独立文件2

独立文件3

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息